Recording of ¥384 million in research and development expenses
First written in FY2017-Q3. 22 of 29 entries say "Restated". Latest entry: FY2026.
95 other companies' latest entry also says "Other".
- FY2026Higher R&D expense and staff numbersAnnual report
「R&D is conducted in each segment, with 36 R&D staff representing 5.4% of total employees. R&D expense for the consolidated fiscal year was ¥875 million,」
R&D staff numbered 36, representing 5.4% of total employees, and R&D expense was ¥875 million, indicating an expansion in the scale of R&D. - FY2026-H1Higher Research and Development ExpensesAnnual report
「Total R&D expense for the interim consolidated fiscal period was ¥374 million. There were no significant changes in the status of the Group's R&D activities during the interim consolidated fiscal period.」
While stating that there were no significant changes in the status of R&D activities, the company reported that R&D expense increased from ¥299 million in the same period of the previous year to ¥374 million. - FY2025-H1RestatedAnnual report
「Total R&D expense for the interim consolidated fiscal period was ¥299 million. There were no significant changes in the status of the Group's R&D activities during the interim consolidated fiscal period.」
The company stated that there were no significant changes in R&D activities and recorded R&D expense of ¥299 million for the interim consolidated fiscal period. - FY2024Higher R&D expense and continued new product developmentAnnual report
「The company has 31 R&D staff, representing 5.0% of total employees. R&D expense for the consolidated fiscal year was ¥717 million,」
R&D expense increased from ¥658 million in the previous fiscal year to ¥717 million. R&D staff numbered 31, representing 5.0% of total employees. The company described development achievements including a suction-type face picker, Semflex-SP, SBS+S, S3con-M and USFG. - FY2024-Q3RestatedAnnual report
「Total R&D expense for the nine-month cumulative period of the current consolidated fiscal year was ¥439 million. There were no significant changes in the status of the Group's R&D activities during the nine-month cumulative period of the current consolidated fiscal year.」
The company stated that there were no significant changes in R&D activities and recorded R&D expense of ¥439 million. - FY2024-Q2RestatedAnnual report
「Total R&D expense for the six-month cumulative period of the current consolidated fiscal year was ¥268 million. There were no significant changes in the status of the Group's R&D activities during the six-month cumulative period of the current consolidated fiscal year.」
The company stated that there were no significant changes in R&D activities and recorded R&D expense of ¥268 million. - FY2024-Q1RestatedAnnual report
「Total R&D expense for the three-month cumulative period of the current consolidated fiscal year was ¥130 million. There were no significant changes in the status of the Group's R&D activities during the three-month cumulative period of the current consolidated fiscal year.」
The company stated that there were no significant changes in R&D activities and reported total R&D expense of ¥130 million for the three-month cumulative period of the current consolidated fiscal year. - FY2023-Q3RestatedAnnual report
「Total R&D expense for the nine-month cumulative period of the current consolidated fiscal year was ¥424 million. There were no significant changes in the status of the Group's R&D activities during the nine-month cumulative period of the current consolidated fiscal year.」
The company stated that there were no significant changes in R&D activities and recorded R&D expense of ¥424 million. - FY2023-Q2RestatedAnnual report
「Total R&D expense for the six-month cumulative period of the current consolidated fiscal year was ¥262 million. There were no significant changes in the status of the Group's R&D activities during the six-month cumulative period of the current consolidated fiscal year.」
The company stated that there were no significant changes in R&D activities and recorded R&D expense of ¥262 million. - FY2022AdvancedAnnual report
「In response to a request from a major supermarket to reduce the heavy labor involved in transferring cases from single-product pallets to six-wheel carts, the company developed the “Transship Cart Loader,” a single-product case transfer machine in its series of automated case depalletizing and palletizing products.」
The company described specific new product development in its R&D activities, including the Transship Cart Loader. Annual R&D expense was ¥600 million, and R&D staff numbered 30. - FY2022-Q3RestatedAnnual report
「Total R&D expense for the nine-month cumulative period of the current consolidated fiscal year was ¥382 million. There were no significant changes in the status of the Group's R&D activities during the nine-month cumulative period of the current consolidated fiscal year.」
The company stated that there were no significant changes in R&D activities and recorded R&D expense of ¥382 million. - FY2022-Q2RestatedAnnual report
「Total R&D expense for the six-month cumulative period of the current consolidated fiscal year was ¥248 million. There were no significant changes in the status of the Group's R&D activities during the six-month cumulative period of the current consolidated fiscal year.」
The company stated that there were no significant changes in R&D activities and reported total R&D expense of ¥248 million for the six-month cumulative period of the current consolidated fiscal year. - FY2022-Q1RestatedAnnual report
「Total R&D expense for the three-month cumulative period of the current consolidated fiscal year was ¥127 million. There were no significant changes in the status of the Group's R&D activities during the three-month cumulative period of the current consolidated fiscal year.」
The company stated that there were no significant changes in R&D activities and reported total R&D expense of ¥127 million for the three-month cumulative period of the current consolidated fiscal year. - FY2021AdvancedAnnual report
「The Precision Machinery Division developed a new image-measurement function, “SSV” (Seibu Scope Vision), for wire electrical-discharge machines.」
In addition to annual R&D expense of ¥665 million and 33 R&D staff, the company described specific new product and function development achievements in its Transport Machinery, Industrial Machinery and Precision Machinery businesses. In Precision Machinery, it developed SSV and achieved errors of no more than ±1 μm in both form accuracy and pitch accuracy. - FY2021-Q3RestatedAnnual report
「Total R&D expense for the nine-month cumulative period of the current consolidated fiscal year was ¥441 million. There were no significant changes in the status of the Group's R&D activities during the nine-month cumulative period of the current consolidated fiscal year.」
The company stated that there were no significant changes in R&D activities and reported total R&D expense of ¥441 million for the nine-month cumulative period of the current consolidated fiscal year. - FY2021-Q2RestatedAnnual report
「Total R&D expense for the six-month cumulative period of the current consolidated fiscal year was ¥274 million. There were no significant changes in the status of the Group's R&D activities during the six-month cumulative period of the current consolidated fiscal year.」
The company stated that there were no significant changes in R&D activities and recorded R&D expense of ¥274 million. - FY2021-Q1RestatedAnnual report
「Total R&D expense for the three-month cumulative period of the current consolidated fiscal year was ¥136 million. There were no significant changes in the status of the Group's R&D activities during the three-month cumulative period of the current consolidated fiscal year.」
The company stated that there were no significant changes in R&D activities and reported total R&D expense of ¥136 million for the three-month cumulative period of the current consolidated fiscal year. - FY2020AdvancedAnnual report
「The Group is focusing on developing one-of-a-kind products and systems directly linked to “ultra-precision and mechatromation.” It has 32 R&D staff, representing 6.1% of total employees. R&D expense for the consolidated fiscal year was ¥668 million.」
R&D staff increased from 30 to 32, while their share of total employees declined from 6.3% to 6.1%; annual R&D expense was ¥668 million. The company also described specific development achievements, including palletizers/depalletizers, SBS and MPSC-20. - FY2020-Q3RestatedAnnual report
「Total R&D expense for the nine-month cumulative period of the current consolidated fiscal year was ¥435 million. There were no significant changes in the status of the Group's R&D activities during the nine-month cumulative period of the current consolidated fiscal year.」
The company stated that there were no significant changes in R&D activities and reported total R&D expense of ¥435 million for the nine-month cumulative period of the current consolidated fiscal year. - FY2020-Q2RestatedAnnual report
「Total R&D expense for the six-month cumulative period of the current consolidated fiscal year was ¥272 million. There were no significant changes in the status of the Group's R&D activities during the six-month cumulative period of the current consolidated fiscal year.」
The company stated that there were no significant changes in R&D activities and reported total R&D expense of ¥272 million for the six-month cumulative period of the current consolidated fiscal year. - FY2020-Q1RestatedAnnual report
「Total R&D expense for the three-month cumulative period of the current consolidated fiscal year was ¥131 million. There were no significant changes in the status of the Group's R&D activities during the three-month cumulative period of the current consolidated fiscal year.」
The company stated that there were no significant changes in R&D activities and reported total R&D expense of ¥131 million for the three-month cumulative period of the current consolidated fiscal year. - FY2019-Q3RestatedAnnual report
「Total R&D expense for the nine-month cumulative period of the current consolidated fiscal year was ¥428 million. There were no significant changes in the status of the Group's R&D activities during the nine-month cumulative period of the current consolidated fiscal year.」
The company stated that there were no significant changes in R&D activities and reported total R&D expense of ¥428 million for the nine-month cumulative period of the current consolidated fiscal year. - FY2019-Q2RestatedAnnual report
「Total R&D expense for the six-month cumulative period of the current consolidated fiscal year was ¥268 million. There were no significant changes in the status of the Group's R&D activities during the six-month cumulative period of the current consolidated fiscal year.」
The company stated that there were no significant changes in R&D activities and reported total R&D expense of ¥268 million for the six-month cumulative period of the current consolidated fiscal year. - FY2019-Q1RestatedAnnual report
「Total R&D expense for the three-month cumulative period of the current consolidated fiscal year was ¥128 million.」
The company stated that there were no significant changes in R&D activities and reported total R&D expense of ¥128 million for the three-month cumulative period of the current consolidated fiscal year. - FY2018-Q3RestatedAnnual report
「Total R&D expense for the nine-month cumulative period of the current consolidated fiscal year was ¥447 million.」
The company stated that there were no significant changes in R&D activities and reported total R&D expense of ¥447 million for the nine-month cumulative period of the current consolidated fiscal year. - FY2018-Q2RestatedAnnual report
「Total R&D expense for the six-month cumulative period of the current consolidated fiscal year was ¥289 million.」
The company stated that there were no significant changes in R&D activities and reported total R&D expense of ¥289 million for the six-month cumulative period of the current consolidated fiscal year. - FY2018-Q1RestatedAnnual report
「Total R&D expense for the three-month cumulative period of the current consolidated fiscal year was ¥138 million.」
While stating that there were no significant changes in R&D activities, the company reported total R&D expense of ¥138 million for the three-month cumulative period of the current consolidated fiscal year. - FY2017RestatedAnnual report
「R&D expense for the consolidated fiscal year was ¥583 million, and the results of R&D and R&D expense for each segment were as follows.」
Annual R&D expense was ¥583.53 million, with product and system development conducted in each segment. - FY2017-Q3First statedAnnual report
「Total R&D expense for the nine-month cumulative period of the current consolidated fiscal year was ¥384 million.」
The total R&D expense for the nine-month cumulative period of the current consolidated fiscal year was stated as ¥384 million.